Cost-effectiveness analysis of antithrombotic therapy in nonurgent percutaneous coronary intervention

Pharmacotherapy

Volumn 26, Issue 5 I, 2006, Pages 609-618

  Summers, Kelly M ^a   Holdford, David A ^b   Crouch, Michael A ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Antithrombotic therapy; Bivalirudin; Glycoprotein IIb IIIa inhibitor; GP IIb IIIa; PCI; Percutaneous coronary intervention; UFH; Unfractionated heparin

Indexed keywords

ABCIXIMAB; ANTICOAGULANT AGENT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN DERIVATIVE; HIRULOG;

ARTICLE; BLEEDING; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DIAGNOSIS RELATED GROUP; DOSE RESPONSE; DRUG COST; HEART INFARCTION; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZATION; REVASCULARIZATION; THROMBOCYTOPENIA; THROMBOSIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ANTITHROMBINS; CORONARY DISEASE; COST-BENEFIT ANALYSIS; DATABASES, FACTUAL; DECISION SUPPORT TECHNIQUES; DRUG COSTS; FIBRINOLYTIC AGENTS; HEPARIN; HIRUDINS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PEPTIDE FRAGMENTS; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 33646347359     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.5.609     Document Type: Article

References (25)

1. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCA1 2005 guideline update for percutaneous coronary intervention, summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (ACC/AHA/SCA1 writing committee to update the 2001 guidelines for percutaneous coronary intervention). Circulation 2006;113:156-75.
2. Cheng JWM. Efficacy of glycoprotein IIb/IIIa-receptor inhibitors during percutaneous coronary intervention. Am J Health-Syst Pharm 2002;59:S5-14.
3. Popma JJ, Berger P, Ohman EM, Harrington RA, Grines C, Weitz J. Antithrombotic therapy during percutaneous coronary intervention: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126(suppl 3):S576-99.
4. Crouch MA, Nappi JM, Cheang KI. Glycoprotein IIb/IIIa receptor inhibitors in percutaneous coronary intervention and acute coronary syndrome. Ann Pharmacother 2003;37:860-75.
5. Karvouni E, Katritsis DG, Ioannidis JPA. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol 2003;41:26-32.
6. Caron MF, McKendall GR. Bivalirudin in percutaneous coronary intervention. Am J Health-Syst Pharm 2003;60:1841-9.
7. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-63.
8. Erratum in JAMA 2003;289:1638.
9. Sanchez LA, Lee JT. Applying pharmacoeconomics: modeling data from internal and external sources. Am J Health-Syst Pharm 2000;57:146-58.
10. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of platelet IIb/IIIa inhibitor for stenting. Lancet 1998;352:87-92.
11. The ESPRIT Investigators. Novel dosing of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo-controlled trial. Lancet 2000;356:2037-44.
12. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularizations. N Engl J Med 2001;344:1888-94.
13. Lincoff AM, Kleiman NS, Kereiakes DJ, et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004;292:696-703.
14. Rao AK, Pratt C, Berke A, et al. Thombolysis in myocardial infarction (TIMI) trial, phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1-11.
15. Hart AC, Schmidt K, eds. DRG expert, 21st ed. Salt Lake City: Ingenix Publishing, 2004.
16. Intellimed International Corporation. Myhealthscore.com: the online coder. Available from www.myhealthscore.com. Accessed September 18, 2004.
17. Gordy TR, ed. Current procedural terminology 2004. Chicago: American Medical Association Press, 2004.
18. Coons JC, Seybert A, Saul MI, Kirsci L, Kane-Gill SL. Outcomes and costs of abciximab versus eptifibatide for percutaneous coronary intervention. Ann Pharmacother 2005;39:1621-6.
19. Lincoff AM, Bittl JA, Kleiman NS, et al. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the randomized evaluation of PCI linking Angiomax to reduced clinical events [REPLACE]-1 trial). Am J Cardiol 2004;93:1092-6.
20. Fleming T, ed. Drug topics red book, 108th ed. Stamford, CT: Thomson Healthcare, 2004.
21. Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the comparison of abciximab complications with hirulog for ischemic events trial (CACHET). Am Heart J 2002;143:847-53.
22. The Medicines Company. Angiomax (bivalirudin) package insert. Parsippany, NJ; 2005.
23. Compton A. A practical cost analysis of bivalirudin. Pharmacotherapy 2002;22(6 pt 2):119S-27.
24. Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina: final reanalysis of the bivalirudin angioplasty study. Am Heart J 2001;142:952-9.
25. Cohen DJ, Lincoff AM, Lavelle TA, et al. Economic evaluation of bivalirudin with provisional glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for percutaneous coronary intervention. J Am Coll Cardiol 2004;44:1792-800.